×
News Home

Do Traders Think Novartis AG (NVS) Can Turn Around Friday?

Friday, December 03, 2021 03:01 PM | InvestorsObserver Analysts
Do Traders Think Novartis AG (NVS) Can Turn Around Friday?

Overall market sentiment has been down on Novartis AG (NVS) stock lately. NVS receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,bearish
Novartis AG has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on NVS!

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With NVS Stock Today?

Novartis AG (NVS) stock is trading at $79.84 as of 2:50 PM on Friday, Dec 3, a loss of -$0.11, or -0.14% from the previous closing price of $79.95. Volume today is 1,709,304 compared to average volume of 2,278,991. The stock has traded between $79.64 and $80.76 so far today. To see InvestorsObserver's Sentiment Score for Novartis AG click here.

More About Novartis AG

Novartis AG develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The firm sells its products globally, with the United States representing close to one third of total revenue. Click Here to get the full Stock Report for Novartis AG stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App